Journal of Clinical Virology
Volume 47, Issue 1 , Pages 18-22 , January 2010

HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays

  • Sonia Napravnik

      Affiliations

    • The University of North Carolina at Chapel Hill, Department of Medicine, Chapel Hill, NC, United States
    • ,
  • Ada Cachafeiro

      Affiliations

    • The University of North Carolina at Chapel Hill, Department of Microbiology and Immunology, Chapel Hill, NC, United States
    • ,
  • Paul Stewart

      Affiliations

    • The University of North Carolina at Chapel Hill, Department of Biostatistics, Chapel Hill, NC, United States
    • ,
  • Joseph J. Eron Jr.

      Affiliations

    • The University of North Carolina at Chapel Hill, Department of Medicine, Chapel Hill, NC, United States
    • ,
  • Susan A. Fiscus

      Affiliations

    • The University of North Carolina at Chapel Hill, Department of Microbiology and Immunology, Chapel Hill, NC, United States
    • Corresponding Author InformationCorresponding author at: Dept of Microbiology & Immunology, University of North Carolina at Chapel Hill, CB # 7290, 709 Mary Ellen Jones Building, Chapel Hill, NC 27599-7290, United States. Tel.: +1 919 966 6872; fax: +1 919 966 9873.

Received 1 July 2009 ,Revised 25 September 2009 ,Accepted 4 October 2009.

References 

  1. Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, Miller V, et al. HIV-1 viral load assays for resource-limited settings. PLoS Med. 2006;3(10):1743–1750
  2. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron JJ. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr. 2005;40(1):34–40
  3. Hatano H, Hunt P, Weidler J, Coakley E, Hoh R, Liegler T, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis. 2006;43(10):1329–1336
  4. DART Virology Group and Trial Team . Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006;20(10):1391–1399
  5. Vergne L, Malonga-Mouellet G, Mistoul I, Mavoungou R, Mansary H, Peeters M, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr. 2002;29(2):165–168
  6. Adje C, Cheingsong R, Roels TH, Maurice C, Djomand G, Verbiest W, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan Cote d’Ivoire. J Acquir Immune Defic Syndr. 2001;26(5):501–506
  7. Hosseinipour M, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high level nucleotide reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23(9):1127–1134
  8. Malmsten A, Shao XW, Aperia K, Corrigan GE, Sandstrom E, Kallander CF, et al. HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol. 2003;71(3):347–359
  9. Malmsten A, Shao XW, Sjodahl S, Fredriksson EL, Pettersson I, Leitner T, et al. Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol. 2005;76(3):291–296
  10. Napravnik S, Eron JJ, McKaig RG, Heine AD, Menezes P, Quinlivan E. Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care. 2006;18(7):45–50
  11. Shao XW, Malmsten A, Lennerstrand J, Sonnerborg A, Unge T, Gronowitz JS, et al. Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing. AIDS. 2003;17(10):1463–1471
  12. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2008. Top HIV Med. 2008;16(5):138–145
  13. Iqbal HS, Balakrishnan P, Cecelia AJ, Solomon S, Kumarasamy N, Madhavan V, et al. Use of an HIV-1 reverse-transcriptase enzyme-activity assay to measure HIV-1 viral load as a potential alternative to nucleic acid-based assay for monitoring antiretroviral therapy in resource-limited settings. J Med Microbiol. 2007;56(Pt 12):1611–1614
  14. Braun J, Plantier JC, Hellot MF, Tuaillon E, Gueudin M, Damond F, et al. A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes. AIDS. 2003;17(3):331–336
  15. Greengrass VL, Turnbull SP, Hocking J, Dunne AL, Tachedjian G, Corrigan GE, et al. Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring. Curr HIV Res. 2005;3(2):183–190
  16. Steegen K, Luchters S, De Cabooter N, Reynaerts J, Mandaliya K, Plum J, et al. Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings. J Virol Methods. 2007;146(1–2):178–187
  17. Sivapalasingam S, Essajee S, Nyambi PN, Itri V, Hanna B, Holzman R, et al. Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for resource-limited settings. J Clin Microbiol. 2005;43(8):3793–3796
  18. Jennings C, Fiscus SA, Crowe SM, Danilovic AD, Morack RT, Scianna S, et al. Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol. 2005;43(12):5950–5956
  19. Mine M, Bedi K, Maruta T, Madziva D, Tau M, Zana T, et al. Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: a decentralization pilot study. J Virol Methods. 2009;159(1):93–97
  20. Greengrass VL, Plate MM, Steele PM, Denholm JT, Cherry CL, Morris LM, et al. Evaluation of the Cavidi ExaVir Load assay (version 3) for plasma human immunodeficiency virus type 1 load monitoring. J Clin Microbiol. 2009;47(9):3011–3013
  21. Greengrass V, Lohman B, Morris L, Plate M, Steele PM, Watson JK, et al. Assessment of the low-cost Cavidi ExaVir load assay for monitoring HIV viral load in pediatric and adult patients. J Acquir Immune Defic Syndr. 2009;
  22. Seyoum E, Wolday D, Girma M, Malmsten A, Meselle T, Gronowitz JS, et al. Reverse transcriptase activity for quantitation of HIV-1 subtype C in plasma: relation to RNA copy number and CD4 T-cell count. J Med Virol. 2006;78(2):161–168
  23. Stevens G, Rekhviashvili N, Scott LE, Gonin R, Stevens W. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol. 2005;43(2):857–861
  24. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007;44(3):447–452
  25. Motakis D, Parniak MA. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46(6):1851–1856
  26. Basson AE, Ntsala M, Martinson N, Tlale E, Corrigan GE, Shao X, et al. Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2008;49(5):538–543
  27. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15(15):1951–1957
  28. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005;192(1):24–29

☆ Presented in part at the 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5–8, 2006, and the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3–6, 2008.

PII: S1386-6532(09)00491-0

doi: 10.1016/j.jcv.2009.10.001

Journal of Clinical Virology
Volume 47, Issue 1 , Pages 18-22 , January 2010

Article Tools

* Image Usage & Resolution